The critical role of inflammation in atherosclerosis has sparked interest in clinical trials investigating anti-inflammatory therapies, such as the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) with the IL-1 inhibitor canakinumab [243] and colchicine studies [244,245,246] with potential interest in cardio-oncology. The gene discussed is IL1B; the disease is atherosclerosis.